BiomeSense
BiomeSense is a Chicago-based biotechnology company focused on developing technologies for continuous, at-home monitoring of the human microbiome.
Profile
Develops technology for continuous at-home monitoring and AI analysis of gut microbiome data.
BiomeSense is a Chicago-based biotechnology company focused on developing technologies for continuous, at-home monitoring of the human microbiome. Founded by Kevin Honaker, the company aims to leverage AI and big data to unlock the potential of microbiome precision medicine. BiomeSense's platform combines GutLab technology for continuous microbiome data generation with the MetaBiome AI platform for analysis, targeting clinically relevant shifts in microbiome composition.
The company has raised undisclosed funding rounds, with recent efforts directed toward expanding its presence in Canada and the UK, while laying groundwork for US and European markets. BiomeSense positions itself as a partner for scientists and companies in the microbiome field, offering longitudinal data and AI-driven insights. The company's technology has potential applications in oncology, with early data suggesting the gut microbiome may serve as a biomarker for tumor burden. With a small team of 1-10 employees, BiomeSense operates in the competitive gut health tech space alongside dozens of other startups targeting this emerging market.
Who buys this
- Pharmaceutical companies developing microbiome-based therapies
- Oncology researchers studying gut-cancer connections
- Nutritional therapy practitioners tracking microbiome changes
- Academic institutions conducting microbiome research
- Biotech firms specializing in personalized medicine
Strengths and what to watch
Strengths
- Proprietary GutLab technology enables continuous microbiome monitoring unlike periodic lab tests
- MetaBiome AI platform can identify clinically relevant microbiome patterns over time
- Early data suggests potential novel biomarkers for cancer treatment monitoring
Watch for
- Undisclosed funding amounts make financial trajectory unclear
- Small team size (1-10 employees) may limit execution capacity
- Highly competitive space with many gut health startups vying for market share
Key Information
- Founded
- 2018
- Headquarters
- Chicago, USA
Frequently Asked Questions
What does BiomeSense do?
BiomeSense develops continuous at-home microbiome monitoring technology combining GutLab hardware with MetaBiome AI analytics. Their platform tracks gut bacteria changes over time, targeting precision medicine applications. The Chicago-based biotech focuses on clinically relevant microbiome shifts, particularly for oncology research and therapeutic development. (42 words)
How does BiomeSense's technology work?
BiomeSense's system uses GutLab devices for continuous microbiome data collection at home, unlike periodic lab tests. Their MetaBiome AI platform analyzes longitudinal patterns, identifying clinically significant bacterial changes. This approach aims to detect biomarkers for conditions like cancer through gut bacteria monitoring. (44 words)
What makes BiomeSense different from other gut health startups?
BiomeSense specializes in continuous monitoring rather than snapshot testing, enabled by proprietary GutLab technology. Their AI platform analyzes microbiome changes over time, targeting medical applications like oncology biomarkers. The company focuses on pharmaceutical and research partnerships rather than direct-to-consumer testing. (46 words)
Is BiomeSense's technology used in cancer research?
Early BiomeSense data suggests gut microbiome patterns may serve as tumor burden biomarkers. Their platform helps oncology researchers track bacterial population shifts, potentially enabling non-invasive cancer monitoring. The technology is being explored for therapeutic development partnerships with pharmaceutical companies. (45 words)
Where is BiomeSense available?
BiomeSense is expanding into Canada and the UK while laying groundwork for US and European markets. The Chicago-based company targets research institutions and biotech firms rather than direct consumer sales. Their business model focuses on partnerships for microbiome data collection and analysis. (47 words)
Who funds BiomeSense?
BiomeSense has raised undisclosed funding rounds to develop its monitoring technology and AI platform. With 1-10 employees, the startup operates in the competitive gut health tech space. Financial details remain private, but expansion plans indicate ongoing investment in international market growth. (45 words)
Sources
- www.linkedin.com — Expansion plans into Canada, UK, US and Europe
- www.linkedin.com — Bioinformatics focus on microbiome-health connections
- www.biomesense.com — Company's technology platform and mission statement
- www.crunchbase.com — Company size (1-10 employees) and founder information